Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jared Gollob

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Orphanet Journal of Rare Diseases|September 5, 2015
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose studyOle B Suhr, Teresa Coelho, Juan Buades, et al.
Plos One|September 2, 2016
Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like CellsChristoph J Niemietz, Vanessa Sauer, Jacqueline Stella, et al.
Orphanet Journal of Rare Diseases|July 10, 2020
A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosisTeresa Coelho, David Adams, Isabel Conceição, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|October 11, 2015
ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipientsJens Gottlieb, Martin R Zamora, Tony Hodges, et al.
Circulation|December 28, 2018
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated AmyloidosisScott D Solomon, David Adams, Arnt Kristen, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid LeukemiaSamarpana Chakraborty, Claudia Morganti, Bianca Rivera Pena, et al.
Leukemia|February 17, 2026
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemiaSamarpana Chakraborty, Claudia Morganti, Kimberly Zaldana, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Orphanet Journal of Rare Diseases|September 5, 2015
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose studyOle B Suhr, Teresa Coelho, Juan Buades, et al.
Plos One|September 2, 2016
Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like CellsChristoph J Niemietz, Vanessa Sauer, Jacqueline Stella, et al.
Orphanet Journal of Rare Diseases|July 10, 2020
A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosisTeresa Coelho, David Adams, Isabel Conceição, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|October 11, 2015
ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipientsJens Gottlieb, Martin R Zamora, Tony Hodges, et al.
Circulation|December 28, 2018
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated AmyloidosisScott D Solomon, David Adams, Arnt Kristen, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid LeukemiaSamarpana Chakraborty, Claudia Morganti, Bianca Rivera Pena, et al.
Leukemia|February 17, 2026
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemiaSamarpana Chakraborty, Claudia Morganti, Kimberly Zaldana, et al.
Pageof 2